DS-1 (drug)

From Wikipedia, the free encyclopedia
DS-1
DS-1.svg
Identifiers
  • 4-chloro-N-(6,8-dibromo-2-thiophen-2-ylimidazo[1,2-a]pyridin-3-yl)benzamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
CompTox Dashboard (EPA)
ECHA InfoCard100.209.966 Edit this at Wikidata
Chemical and physical data
FormulaC18H10Br2ClN3OS
Molar mass511.62 g·mol−1
3D model (JSmol)
SMILES
  • s4cccc4-c2nc1c(Br)cc(Br)cn1c2NC(=O)c(cc3)ccc3Cl
  

DS-1 is a drug from the imidazopyridine family, which is the first drug developed that acts as a GABAA receptor positive allosteric modulator (PAM) selective for the α4β3δ subtype, which is not targeted by other GABAA receptor PAMs such as the benzodiazepines or other nonbenzodiazepine drugs. Novel selective drugs such as DS-1 should prove useful in the study of this receptor subtype.[1]

See also[]

References[]

  1. ^ Wafford KA, van Niel MB, Ma QP, Horridge E, Herd MB, Peden DR, et al. (January 2009). "Novel compounds selectively enhance delta subunit containing GABA A receptors and increase tonic currents in thalamus". Neuropharmacology. 56 (1): 182–9. doi:10.1016/j.neuropharm.2008.08.004. PMID 18762200. S2CID 207224202.
Retrieved from ""